Alopecia areata: What's new in epidemiology, pathogenesis, diagnosis, and therapeutic options?

Journal of Dermatological Science

Volumn 86, Issue 1, 2017, Pages 3-12

  Dainichi, Teruki ^a   Kabashima, Kenji ^a,b,c  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Alopecia areata; Autoimmunity; Diagnosis; Epidemiology; Genetics; Treatment

Indexed keywords

ABATACEPT; APREMILAST; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CHEMOKINE; DIPHENCYPRONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE INHIBITOR; SQUARIC ACID DIBUTYLESTER; STEROID; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UTSTEKINUMAB; VITAMIN; GLUCOCORTICOID;

ALOPECIA AREATA; COMORBIDITY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; EFFECTOR CELL; EPIDEMIOLOGICAL DATA; EPILUMINESCENCE MICROSCOPY; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNE PRIVILEGE; IMMUNITY; INCIDENCE; LOW LEVEL LASER THERAPY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PHOTOTHERAPY; PROGNOSIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTE RICH PLASMA; TREATMENT INDICATION; TRICHOSCOPY; VITAMIN D DEFICIENCY; AUTOIMMUNE DISEASES; BLOOD; CRYOTHERAPY; DRUG PULSE THERAPY; HAIR FOLLICLE; IMMUNOLOGY; IMMUNOTHERAPY; PRACTICE GUIDELINE; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALOPECIA AREATA; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BIOMARKERS; CHEMOKINES; CRYOTHERAPY; DERMOSCOPY; GLUCOCORTICOIDS; HAIR FOLLICLE; HUMANS; IMMUNOTHERAPY; INCIDENCE; PHOTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PULSE THERAPY, DRUG; QUALITY OF LIFE; T-LYMPHOCYTES, REGULATORY;

EID: 85005810406     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.10.004     Document Type: Review

References (145)

1. [1] Mirzoyev, S.A., Schrum, A.G., Davis, M.D., Torgerson, R.R., Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J. Invest. Dermatol. 134 (2014), 1141–1142.
2. [2] Andersen, L.K., Davis, M.D., Prevalence of skin and skin-related diseases in the rochester epidemiology project and a comparison with other published prevalence studies. Dermatology 232 (2016), 344–352.
3. [3] Jang, Y.H., Park, K.H., Kim, S.L., Lim, H.J., Lee, W.J., Lee, S.J., et al. Alopecia areata in the elderly: a 10-year retrospective study. Ann. Dermatol. 27 (2015), 411–416.
4. [4] Chu, S.Y., Chen, Y.J., Tseng, W.C., Lin, M.W., Chen, T.J., Hwang, C.Y., et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J. Am. Acad. Dermatol. 65 (2011), 949–956.
5. [5] Serarslan, G., Savas, N., Yenin, J.Z., Is atopy and autoimmunity more prevalent in patients with alopecia areata? A comparative study. J. Eur. Acad. Dermatol. Venereol. 26 (2012), 720–723.
6. [6] Mohan, G.C., Silverberg, J.I., Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 151 (2015), 522–528.
7. [7] Miller, R., Conic, R.Z., Bergfeld, W., Mesinkovska, N.A., Prevalence of comorbid conditions and sun-induced skin cancers in patients with alopecia areata. J. Invest. Dermatol. Symp. Proc. 17 (2015), 61–62.
8. [8] Garzorz, N., Alsisi, M., Todorova, A., Atenhan, A., Thomas, J., Lauffer, F., et al. Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases. J. Eur. Acad. Dermatol. Venereol. 29 (2015), 2429–2435.
9. [9] Kang, J.H., Lin, H.C., Kao, S., Tsai, M.C., Chung, S.D., Alopecia areata increases the risk of stroke: a 3-year follow-up study. Sci. Rep., 5, 2015, 11718.
10. [10] Huang, K.P., Joyce, C.J., Topaz, M., Guo, Y., Mostaghimi, A., Cardiovascular risk in patients with alopecia areata (AA): a propensity-matched retrospective analysis. J. Am. Acad. Dermatol. 75 (2016), 151–154.
11. [11] Mostaghimi, A., Qureshi, S., Joyce, C., Guo, Y., Huang, K.P., Reduced incidence of skin cancer in patients with alopecia areata: a retrospective cohort study. Cancer Epidemiol. 41 (2016), 129–131.
12. [12] Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2163–2196.
13. [13] Hay, R.J., Johns, N.E., Williams, H.C., Bolliger, I.W., Dellavalle, R.P., Margolis, D.J., et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Invest. Dermatol. 134 (2014), 1527–1534.
14. [14] Karimkhani, C., Boyers, L.N., Naghavi, M., Coffeng, L.E., Lott, J.P., Wulf, S., et al. The global burden of disease associated with alopecia areata. Br. J. Dermatol. 172 (2015), 1424–1426.
15. [15] Dubois, M., Baumstarck-Barrau, K., Gaudy-Marqueste, C., Richard, M.A., Loundou, A., Auquier, P., et al. Quality of life in alopecia areata: a study of 60 cases. J. Invest. Dermatol. 130 (2010), 2830–2833.
16. [16] Matzer, F., Egger, J.W., Kopera, D., Psychosocial stress and coping in alopecia areata: a questionnaire survey and qualitative study among 45 patients. Acta Derm. Venereol. 91 (2011), 318–327.
17. [17] Chu, S.Y., Chen, Y.J., Tseng, W.C., Lin, M.W., Chen, T.J., Hwang, C.Y., et al. Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study. Br. J. Dermatol. 166 (2012), 525–531.
18. [18] Bilgic, O., Bilgic, A., Bahali, K., Bahali, A.G., Gurkan, A., Yilmaz, S., Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J. Eur. Acad. Dermatol. Venereol. 28 (2014), 1463–1468.
19. [19] Endo, Y., Miyachi, Y., Arakawa, A., Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur. J. Dermatol. 22 (2012), 531–536.
20. [20] Fabbrocini, G., Panariello, L., De Vita, V., Vincenzi, C., Lauro, C., Nappo, D., et al. Quality of life in alopecia areata: a disease-specific questionnaire. J. Eur. Acad. Dermatol. Venereol. 27 (2013), e276–e281.
21. [21] Rencz, F., Gulacsi, L., Pentek, M., Wikonkal, N., Baji, P., Brodszky, V., Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br. J. Dermatol. 175 (2016), 561–571.
22. [22] Liu, L.Y., King, B.A., Craiglow, B.G., Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J. Am. Acad. Dermatol. 75 (2016), 806–812.
23. [23] Biran, R., Zlotogorski, A., Ramot, Y., The genetics of alopecia areata: new approaches, new findings, new treatments. J. Dermatol. Sci 78 (2015), 11–20.
24. [24] Petukhova, L., Duvic, M., Hordinsky, M., Norris, D., Price, V., Shimomura, Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466 (2010), 113–117.
25. [25] Ito, T., Ito, N., Saatoff, M., Hashizume, H., Fukamizu, H., Nickoloff, B.J., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J. Invest. Dermatol. 128 (2008), 1196–1206.
26. [26] Betz, R.C., Petukhova, L., Ripke, S., Huang, H., Menelaou, A., Redler, S., et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat. Commun., 6, 2015, 5966.
27. [27] Luo, S., Rubinsztein, D.C., BCL2L11/BIM: a novel molecular link between autophagy and apoptosis. Autophagy 9 (2013), 104–105.
28. [28] Melum, E., Franke, A., Schramm, C., Weismuller, T.J., Gotthardt, D.N., Offner, F.A., et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat. Genet. 43 (2011), 17–19.
29. [29] Wang, R., Zhu, J., Dong, X., Shi, M., Lu, C., Springer, T.A., GARP regulates the bioavailability and activation of TGFbeta. Mol. Biol. Cell 23 (2012), 1129–1139.
30. [30] Wang, R., Kozhaya, L., Mercer, F., Khaitan, A., Fujii, H., Unutmaz, D., Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13439–13444.
31. [31] Zhernakova, A., Elbers, C.C., Ferwerda, B., Romanos, J., Trynka, G., Dubois, P.C., et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. Am. J. Hum. Genet. 86 (2010), 970–977.
32. [32] Petukhova, L., Christiano, A.M., Functional interpretation of genome-wide association study evidence in alopecia areata. J. Invest. Dermatol. 136 (2016), 314–317.
33. [33] John, K.K., Brockschmidt, F.F., Redler, S., Herold, C., Hanneken, S., Eigelshoven, S., et al. Genetic variants in CTLA4 are strongly associated with alopecia areata. J. Invest. Dermatol. 131 (2011), 1169–1172.
34. [34] Redler, S., Albert, F., Brockschmidt, F.F., Herold, C., Hanneken, S., Eigelshoven, S., et al. Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br. J. Dermatol. 167 (2012), 1360–1365.
35. [35] Jagielska, D., Redler, S., Brockschmidt, F.F., Herold, C., Pasternack, S.M., Garcia Bartels, N., et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J. Invest. Dermatol. 132 (2012), 2192–2197.
36. [36] Forstbauer, L.M., Brockschmidt, F.F., Moskvina, V., Herold, C., Redler, S., Herzog, A., et al. Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur. J. Hum. Genet. 20 (2012), 326–332.
37. [37] Seok, H., Suh, D.W., Jo, B., Lee, H.B., Jang, H.M., Park, H.K., et al. Association between TLR1 polymorphisms and alopecia areata. Autoimmunity 47 (2014), 372–377.
38. [38] Redler, S., Angisch, M., Heilmann, S., Wolf, S., Barth, S., Basmanav, B.F., et al. Immunochip-based analysis: high-density genotyping of immune-related loci sheds further light on the autoimmune genetic architecture of alopecia areata. J. Invest. Dermatol. 135 (2015), 919–921.
39. [39] Fischer, J., Degenhardt, F., Hofmann, A., Redler, S., Basmanav, F.B., Heilmann-Heimbach, S., et al. Genome-wide analysis of copy number variants in alopecia areata in a Central European cohort reveals association with MCHR2. Exp. Dermatol., 2016, 10.1111/exd.13123 Jun 16 Epub ahead of print.
40. [40] Kaufman, G., d'Ovidio, R., Kaldawy, A., Assy, B., Ullmann, Y., Etzioni, A., et al. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic?. Exp. Dermatol. 19 (2010), e347–349.
41. [41] Tojo, G., Fujimura, T., Kawano, M., Ogasawara, K., Kambayashi, Y., Furudate, S., et al. Comparison of interleukin-17- producing cells in different clinical types of alopecia areata. Dermatology 227 (2013), 78–82.
42. [42] Tanemura, A., Oiso, N., Nakano, M., Itoi, S., Kawada, A., Katayama, I., Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology 226 (2013), 333–336.
43. [43] Han, Y.M., Sheng, Y.Y., Xu, F., Qi, S.S., Liu, X.J., Hu, R.M., et al. Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata. J. Dermatol. 42 (2015), 981–988.
44. [44] Abou Rahal, J., Kurban, M., Kibbi, A.G., Abbas, O., Plasmacytoid dendritic cells in alopecia areata: missing link?. J. Eur. Acad. Dermatol. Venereol. 30 (2014), 119–123.
45. [45] Bertolini, M., Zilio, F., Rossi, A., Kleditzsch, P., Emelianov, V.E., Gilhar, A., et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One, 9, 2014, e94260.
46. [46] Yoshimasu, T., Uede, M., Kanazawa, N., Mikita, N., Yamamoto, Y., Ito, T., et al. Involvement of FcvarepsilonR1alpha immunopositive cells in alopecia areata with atopic dermatitis and a high titer of serum immunoglobulin E. Eur. J. Dermatol. 24 (2014), 500–503.
47. [47] Jang, Y.H., Jin, M., Moon, S.Y., Eun, D.H., Lee, W.J., Lee, S.J., et al. Investigation on the role of necroptosis in alopecia areata: a preliminary study. J. Am. Acad. Dermatol. 75 (2016), 436–439.
48. [48] McPhee, C.G., Duncan, F.J., Silva, K.A., King, L.E. Jr., Hogenesch, H., Roopenian, D.C., et al. Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J. Invest. Dermatol. 132 (2012), 1736–1738.
49. [49] Ito, T., Hashizume, H., Shimauchi, T., Funakoshi, A., Ito, N., Fukamizu, H., et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J. Dermatol. Sci. 69 (2013), 140–147.
50. [50] Ito, T., Fujiyama, T., Hashizume, H., Tokura, Y., Antihistaminic drug olopatadine downmodulates T cell chemotaxis toward CXCL10 by reducing CXCR3 expression, F-actin polymerization and calcium influx in patients with alopecia areata. J. Dermatol. Sci. 72 (2013), 68–71.
51. [51] Dai, Z., Xing, L., Cerise, J., Wang, E.H., Jabbari, A., de Jong, A., et al. CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata. J. Immunol., 2016.
52. [52] Saito, M., Ohyama, M., Amagai, M., Exploring the biology of the nail: an intriguing but less-investigated skin appendage. J. Dermatol. Sci. 79 (2015), 187–193.
53. [53] Kang, H., Wu, W.Y., Lo, B.K., Yu, M., Leung, G., Shapiro, J., et al. Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss. J. Invest. Dermatol. 130 (2010), 2677–2680.
54. [54] Shin, B.S., Furuhashi, T., Nakamura, M., Torii, K., Morita, A., Impaired inhibitory function of circulating CD4+CD25+ regulatory T cells in alopecia areata. J. Dermatol. Sci. 70 (2013), 141–143.
55. [55] Tembhre, M.K., Sharma, V.K., T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br. J. Dermatol. 169 (2013), 543–548.
56. [56] Bertolini, M., Pretzlaff, M., Sulk, M., Bahr, M., Gherardini, J., Uchida, Y., et al. VIP, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse. Br. J. Dermatol. 175 (2016), 531–541.
57. [57] Alli, R., Nguyen, P., Boyd, K., Sundberg, J.P., Geiger, T.L., A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J. Immunol. 188 (2012), 477–486.
58. [58] Wang, E.H., Khosravi-Maharlooei, M., Jalili, R.B., Yu, R., Ghahary, A., Shapiro, J., et al. Transfer of alopecia areata to C3H/HeJ mice using cultured lymph node-derived cells. J. Invest. Dermatol. 135 (2015), 2530–2532.
59. [59] Wang, E., Chong, K., Yu, M., Akhoundsadegh, N., Granville, D.J., Shapiro, J., et al. Development of autoimmune hair loss disease alopecia areata is associated with cardiac dysfunction in C3H/HeJ mice. PLoS One, 8, 2013, e62935.
60. [60] Gilhar, A., Keren, A., Shemer, A., d'Ovidio, R., Ullmann, Y., Paus R: autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J. Invest. Dermatol. 133 (2013), 844–847.
61. [61] Kemp, E.H., Sandhu, H.K., Weetman, A.P., McDonagh, A.J., Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata. Br. J. Dermatol. 165 (2011), 1236–1243.
62. [62] Rahoma, S.F., Sandhu, H.K., McDonagh, A.J., Gawkrodger, D.J., Weetman, A.P., Kemp, E.H., Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients. Br. J. Dermatol. 167 (2012), 17–28.
63. [63] Ahn, K.J., Choi, E.A., Kim, J., Lee, J.H., Lee, K.H., Bang, D., et al. Increased retinol-binding protein (RBP) 4 and anti-RBP4 antibody in alopecia areata. Br. J. Dermatol. 165 (2011), 837–844.
64. [64] Ito, T., Bertolini, M., Funakoshi, A., Ito, N., Takayama, T., Biro, T., et al. Birth, life, and death of the MAGE3 hypothesis of alopecia areata pathobiology. J. Dermatol. Sci. 72 (2013), 327–330.
65. [65] Wang, E.H., Yu, M., Breitkopf, T., Akhoundsadegh, N., Wang, X., Shi, F.T., et al. Identification of autoantigen epitopes in alopecia areata. J. Invest. Dermatol. 136 (2016), 1617–1626.
66. [66] Duncan, F.J., Silva, K.A., Johnson, C.J., King, B.L., Szatkiewicz, J.P., Kamdar, S.P., et al. Endogenous retinoids in the pathogenesis of alopecia areata. J. Invest. Dermatol. 133 (2013), 334–343.
67. [67] Aksu Cerman, A., Sarikaya Solak, S., Kivanc Altunay, I., Vitamin D deficiency in alopecia areata. Br. J. Dermatol. 170 (2014), 1299–1304.
68. [68] Katikaneni, R., Seymour, A.W., Gulati, R., Ponnapakkam, T., Gensure, R.C., Therapy for alopecia areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain. J. Invest. Dermatol. Symp. Proc. 17 (2015), 13–15.
69. [69] Inui, S., Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J. Dermatol. 38 (2011), 71–75.
70. [70] Miteva, M., Tosti, A., Hair and scalp dermatoscopy. J. Am. Acad. Dermatol. 67 (2012), 1040–1048.
71. [71] Suzuki, T., Tokura, Y., Ito, T., Similarities of dermoscopic findings in alopecia areata between human and C3H/HeJ mouse. J. Dermatol. Sci. 83 (2016), 154–157.
72. [72] Yoon, T.Y., Lee, D.Y., Kim, Y.J., Lee, J.Y., Kim, M.K., Diagnostic usefulness of a peribulbar eosinophilic infiltrate in alopecia areata. JAMA Dermatol. 150 (2014), 952–956.
73. [73] Watanabe-Okada, E., Amagai, M., Ohyama, M., Histopathological investigation of clinically non-affected perilesional scalp in alopecias detected unexpected spread of disease activities. J. Dermatol. 41 (2014), 802–807.
74. [74] Barahmani, N., Lopez, A., Babu, D., Hernandez, M., Donley, S.E., Duvic, M., Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. Clin. Exp. Dermatol. 35 (2010), 409–416.
75. [75] Inui, S., Noguchi, F., Nakajima, T., Itami, S., Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata. J. Dermatol. 40 (2013), 881–885.
76. [76] Lee, Y., Lee, H.E., Shin, J.M., Sohn, K.C., Im, M., Kim, C.D., et al. Clinical significance of serum high-mobility group box 1 level in alopecia areata. J. Am. Acad. Dermatol. 69 (2013), 742–747.
77. [77] Ono, S., Otsuka, A., Yamamoto, Y., Kataoka, T.R., Koyanagi, I., Miyachi, Y., et al. Serum granulysin as a possible key marker of the activity of alopecia areata. J. Dermatol. Sci 73 (2014), 74–79.
78. [78] Yenin, J.Z., Serarslan, G., Yonden, Z., Ulutas, K.T., Investigation of oxidative stress in patients with alopecia areata and its relationship with disease severity, duration, recurrence and pattern. Clin. Exp. Dermatol. 40 (2015), 617–621.
79. [79] Jabbari, A., Cerise, J.E., Chen, J.C., Mackay-Wiggan, J., Duvic, M., Price, V., et al. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine 7 (2016), 240–247.
80. [80] Uchiyama, M., Egusa, C., Hobo, A., Irisawa, R., Yamazaki, M., Tsuboi, R., Multivariate analysis of prognostic factors in patients with rapidly progressive alopecia areata. J. Am. Acad. Dermatol. 67 (2012), 1163–1173.
81. [81] Messenger, A.G., McKillop, J., Farrant, P., McDonagh, A.J., Sladden, M., British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br. J. Dermatol. 166 (2012), 916–926.
82. [82] Lenane, P., Macarthur, C., Parkin, P.C., Krafchik, B., DeGroot, J., Khambalia, A., et al. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol. 150 (2014), 47–50.
83. [83] Inui, S., Itami, S., Contact immunotherapy-resistant alopecia areata totalis/universalis reactive to topical corticosteroid. J. Dermatol. 42 (2015), 937–939.
84. [84] Kuldeep, C., Singhal, H., Khare, A.K., Mittal, A., Gupta, L.K., Garg, A., Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int. J. Trichol. 3 (2011), 20–24.
85. [85] Kassim, J.M., Shipman, A.R., Szczecinska, W., Siah, T.W., Lam, M., Chalmers, J., et al. How effective is intralesional injection of triamcinolone acetonide compared with topical treatments in inducing and maintaining hair growth in patients with alopecia areata? A critically appraised topic. Br. J. Dermatol. 170 (2014), 766–771.
86. [86] Chu, T.W., AlJasser, M., Alharbi, A., Abahussein, O., McElwee, K., Shapiro, J., Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J. Am. Acad. Dermatol. 73 (2015), 338–340.
87. [87] Samrao, A., Fu, J.M., Harris, S.T., Price, V.H., Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J. Drugs Dermatol. 12 (2013), e36–e40.
88. [88] Shreberkassidim, R., Ramot, Y., Gilula, Z., Zlotogorski, A., A systematic review of pulse steroid therapy for alopecia areata. J. Am. Acad. Dermatol. 74 (2016), 372–374 e371–375.
89. [89] Im, M., Lee, S.S., Lee, Y., Kim, C.D., Seo, Y.J., Lee, J.H., et al. Prognostic factors in methylprednisolone pulse therapy for alopecia areata. J. Dermatol. 38 (2011), 767–772.
90. [90] Sato, M., Amagai, M., Ohyama, M., Detailed clinicopathological characterization of progressive alopecia areata patients treated with i.v. corticosteroid pulse therapy toward optimization of inclusion criteria. J. Dermatol. 41 (2014), 957–963.
91. [91] Senila, S.C., Danescu, S.A., Ungureanu, L., Candrea, E., Cosgarea, R.M., Intravenous methylprednisolone pulse therapy in severe alopecia areata. Indian J. Dermatol. Venereol. Leprol., 81, 2015, 95.
92. [92] Staumont-Salle, D., Vonarx, M., Lengrand, F., Segard, M., Delaporte, E., Pulse corticosteroid therapy for alopecia areata: long-term outcome after 10 years. Dermatology 225 (2012), 81–87.
93. [93] Acikgoz, G., Ozmen, I., Cayirli, M., Yeniay, Y., Kose, O., Pulse methylprednisolone therapy for the treatment of extensive alopecia areata. J. Dermatol. Treat. 25 (2014), 164–166.
94. [94] Lalosevic, J., Gajic-Veljic, M., Bonaci-Nikolic, B., Nikolic, M., Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study. Dermatol. Ther. 28 (2015), 309–317.
95. [95] Smith, A., Trueb, R.M., Theiler, M., Hauser, V., Weibel, L., High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr. Dermatol. 32 (2015), 481–487.
96. [96] Friedland, R., Tal, R., Lapidoth, M., Zvulunov, A., Ben Amitai, D., Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology 227 (2013), 37–44.
97. [97] Alkhalifah, A., Alsantali, A., Wang, E., McElwee, K.J., Shapiro, J., Alopecia areata update: part II. Treatment. J. Am. Acad. Dermatol. 62 (2010), 191–202 quiz 203–194.
98. [98] Ohlmeier, M.C., Traupe, H., Luger, T.A., Bohm, M., Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata–a large retrospective study on 142 patients with a self-controlled design. J. Eur. Acad. Dermatol. Venereol. 26 (2012), 503–507.
99. [99] Chiang, K., Atanaskova Mesinkovska, N., Amoretti, A., Piliang, M.P., Kyei, A., Bergfeld, W.F., Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J. Am. Acad. Dermatol. 71 (2014), 595–597.
100. [100] Chiang, K.S., Mesinkovska, N.A., Piliang, M.P., Bergfeld, W.F., Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J. Invest. Dermatol. Symp. Proc. 17 (2015), 50–55.
101. [101] Salsberg, J.M., Donovan, J., The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch. Dermatol. 148 (2012), 1084–1085.
102. [102] Avitabile, S., Sordi, D., Garcovich, S., Colonna, L., De Luca, A., Nasorri, F., et al. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T-helper (Th)1 and Th17 cells in alopecia areata patients. J. Dermatol. 42 (2015), 98–99.
103. [103] Gulati, N., Lovendorf, M.B., Zibert, J.R., Akat, K.M., Renwick, N., Tuschl, T., et al. Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin. Exp. Dermatol. 24 (2015), 953–957.
104. [104] Vedak, P., Kroshinsky, D., Squaric acid sensitization is not required for response in the treatment of alopecia areata. J. Am. Acad. Dermatol. 73 (2015), 471–476.
105. [105] Ohtsuki, A., Hasegawa, T., Ikeda, S., Treatment of alopecia areata with 308-nm excimer lamp. J. Dermatol. 37 (2010), 1032–1035.
106. [106] Byun, J.W., Moon, J.H., Bang, C.Y., Shin, J., Choi, G.S., Effectiveness of 308-nm excimer laser therapy in treating alopecia areata, determined by examining the treated sides of selected alopecic patches. Dermatology 231 (2015), 70–76.
107. [107] Arakawa, Y., Nomiyama, T., Katoh, N., Three hundred and eight nanometer excimer light therapy for alopecia universalis that is resistant to other treatments: a clinical study of 11 patients. J. Dermatol., 2016, 10.1111/1346-8138.13419 Apr 30 Epub ahead of print.
108. [108] Bayramgurler, D., Demirsoy, E.O., Akturk, A.S., Kiran, R., Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol. Photoimmunol. Photomed. 27 (2011), 325–327.
109. [109] Lee, G.Y., Lee, S.J., Kim, W.S., The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J. Eur. Acad. Dermatol. Venereol. 25 (2011), 1450–1454.
110. [110] Royer, M., Bodemer, C., Vabres, P., Pajot, C., Barbarot, S., Paul, C., et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br. J. Dermatol. 165 (2011), 407–410.
111. [111] Lucas, P., Bodemer, C., Barbarot, S., Vabres, P., Royer, M., Mazereeuw-Hautier, J., Methotrexate in severe childhood alopecia areata: long-term follow-up. Acta Derm. Venereol. 96 (2016), 102–103.
112. [112] Droitcourt, C., Milpied, B., Ezzedine, K., Hubiche, T., Belin, E., Akpadjan, F., et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology 224 (2012), 369–373.
113. [113] Anuset, D., Perceau, G., Bernard, P., Reguiai, Z., Efficacy and safety of methotrexate combined with low- to moderate-dose corticosteroids for severe alopecia areata. Dermatology 232 (2016), 242–248.
114. [114] Vano-Galvan, S., Hermosa-Gelbard, A., Sanchez-Neila, N., Miguel-Gomez, L., Saceda-Corralo, D., Rodrigues-Barata, R., et al. Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine. J. Am. Acad. Dermatol. 74 (2016), 1007–1008.
115. [115] Kanameishi, S., Dainichi, T., Endo, Y., Otsuka, A., T, M., Kabashima, K., Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis. J. Eur. Acad. Dermatol. Venereol., 2016, 10.1111/jdv.13879 Aug 17 Epub ahead of print.
116. [116] Zawar, V.P., Karad, G.M., Liquid nitrogen cryotherapy in recalcitrant alopecia areata: a study of 11 patients. Int. J. Trichol. 8 (2016), 15–20.
117. [117] Papp, K.A., Krueger, J.G., Feldman, S.R., Langley, R.G., Thaci, D., Torii, H., et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J. Am. Acad. Dermatol. 74 (2016), 841–850.
118. [118] Bissonnette, R., Papp, K.A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br. J. Dermatol., 2016.
119. [119] Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J. Allergy Clin. Immunol. 136 (2015), 667–677 (e667).
120. [120] Amano, W., Nakajima, S., Yamamoto, Y., Tanimoto, A., Matsushita, M., Miyachi, Y., et al. JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. J. Dermatol. Sci., 2016, 10.1016/j.jdermsci.2016.09.007 Sep 13 Epub ahead of print.
121. [121] Xing, L., Dai, Z., Jabbari, A., Cerise, J.E., Higgins, C.A., Gong, W., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 20 (2014), 1043–1049.
122. [122] Craiglow, B.G., King, B.A., Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Invest. Dermatol. 134 (2014), 2988–2990.
123. [123] Pieri, L., Guglielmelli, P., Vannucchi, A.M., Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am. J. Hematol. 90 (2015), 82–83.
124. [124] Higgins, E., Al Shehri, T., McAleer, M.A., Conlon, N., Feighery, C., Lilic, D., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J. Allergy Clin. Immunol. 135 (2015), 551–553.
125. [125] Jabbari, A., Dai, Z., Xing, L., Cerise, J.E., Ramot, Y., Berkun, Y., et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine 2 (2015), 351–355.
126. [126] Guttman-Yassky, E., Ungar, B., Noda, S., Suprun, M., Shroff, A., Dutt, R., et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J. Allergy Clin. Immunol. 137 (2016), 301–304.
127. [127] Suarez-Farinas, M., Ungar, B., Noda, S., Shroff, A., Mansouri, Y., Fuentes-Duculan, J., et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J. Allergy Clin. Immunol. 136 (2015), 1277–1287.
128. [128] Gorcey, L., Gordon Spratt, E.A., Leger, M.C., Alopecia universalis successfully treated with adalimumab. JAMA Dermatol. 150 (2014), 1341–1344.
129. [129] Tauber, M., Buche, S., Reygagne, P., Berthelot, J.M., Aubin, F., Ghislain, P.D., et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J. Am. Acad. Dermatol. 70 (2014), 1146–1149.
130. [130] Mackay-Wiggan, J., Nguyen, N., Clark, C., Jabbari, A., Ulerio, G., Furniss, M., et al. Subcutaneous abatacept in the treatment of moderate to severe alopecia areata. J Invest Dermatol, 135, 2015, S41.
131. [131] Keren, A., Shemer, A., Ullmann, Y., Paus, R., Gilhar, A., The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J. Dermatol. Sci. 77 (2015), 74–76.
132. [132] Castela, E., Le Duff, F., Butori, C., Ticchioni, M., Hofman, P., Bahadoran, P., et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 150 (2014), 748–751.
133. [133] Li, Y., Yan, B., Wang, H., Li, H., Li, Q., Zhao, D., et al. Hair regrowth in alopecia areata patients following Stem Cell Educator therapy. BMC Med., 13(87), 2015.
134. [134] Zhao, Y., Glesne, D., Huberman, E., A human peripheral blood monocyte-derived subset acts as pluripotent stem cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2426–2431.
135. [135] Zhao, Y., Jiang, Z., Zhao, T., Ye, M., Hu, C., Zhou, H., et al. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med., 11(160), 2013.
136. [136] Trink, A., Sorbellini, E., Bezzola, P., Rodella, L., Rezzani, R., Ramot, Y., et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br. J. Dermatol. 169 (2013), 690–694.
137. [137] Lattouf, C., Jimenez, J.J., Tosti, A., Miteva, M., Wikramanayake, T.C., Kittles, C., et al. Treatment of alopecia areata with simvastatin/ezetimibe. J. Am. Acad. Dermatol. 72 (2015), 359–361.
138. [138] Coronel-Perez, I.M., Rodriguez-Rey, E.M., Camacho-Martinez, F.M., Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J. Eur. Acad. Dermatol. Venereol. 24 (2010), 481–485.
139. [139] Maubec, E., Laouenan, C., Deschamps, L., Nguyen, V.T., Scheer-Senyarich, I., Wackenheim-Jacobs, A.C., et al. Topical mineralocorticoid receptor blockade limits glucocorticoid-induced epidermal atrophy in human skin. J. Invest. Dermatol. 135 (2015), 1781–1789.
140. [140] Dainichi, T., Hanakawa, S., Kabashima, K., Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J. Dermatol. Sci. 76 (2014), 81–89.
141. [141] Edmonds-Wilson, S.L., Nurinova, N.I., Zapka, C.A., Fierer, N., Wilson, M., Review of human hand microbiome research. J. Dermatol. Sci. 80 (2015), 3–12.
142. [142] Haniffa, M., Gunawan, M., Jardine, L., Human skin dendritic cells in health and disease. J. Dermatol. Sci. 77 (2015), 85–92.
143. [143] Ehling, S., Rossbach, K., Dunston, S.M., Stark, H., Baumer, W., Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo. J. Dermatol. Sci. 83 (2016), 106–115.
144. [144] Cerwenka, A., Lanier, L.L., Natural killer cell memory in infection, inflammation and cancer. Nat. Rev. Immunol. 16 (2016), 112–123.
145. [145] van den Boorn, J.G., Jakobs, C., Hagen, C., Renn, M., Luiten, R.M., Melief, C.J., et al. Inflammasome-dependent induction of adaptive NK cell memory. Immunity 44 (2016), 1406–1421.